Antibiotics For Emerging Pathogens
By Michael A. Fischbach, C. Walsh. Science, 2009
1,757 citations recorded by the source corpus.
Toward New Scaffolds Most existing antibiotics are derived from a small number of core molecular structures or scaffolds. As more and more pathogens emerge that are resistant to existing antibiotics, Fischbach and Walsh (p. 1089) review why renewed efforts must be made to find not only new antibiotics but new scaffolds. Approaches in the areas of natural products, synthesis, and target-based discovery are all yielding promising antibiotics candidates. The battle against resistance should also involve researching narrow-spectrum antibiotics and using combination therapies to extend the usefulness of drugs with high intrinsic resistance rates. Antibiotic-resistant strains of pathogenic bacteria are increasingly prevalent in hospitals and the community. New antibiotics are needed to combat these bacterial pathogens, but progress in developing them has been slow. Historically, most antibiotics have come from a small set of molecular scaffolds whose functional lifetimes have been extended by generations of synthetic tailoring. The emergence of multidrug resistance among the latest generation of pathogens suggests that the discovery of new scaffolds should be a priority. Promising approaches to scaffold discovery are emerging; they include mining underexplored microbial niches for natural products, designing screens that avoid rediscovering old scaffolds, and repurposing libraries of synthetic molecules for use as antibiotics.
Subfields: Molecular Biology, Molecular Medicine, Pharmacology
View Paper: https://www.semanticscholar.org/paper/af65aa71fffbda4543f3e9634a4b848f385ca151
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- S. Lemire
- Hiroki Ando
- D. Kurtböke
- Amberlee Marker
- Liangfang Zhang
- C. J. Hu
- Timothy K. Lu
- Chun-Ming Huang
In Molecular Medicine
In Pharmacology
- D. Kurtböke
- Amberlee Marker
- Liangfang Zhang
- C. J. Hu
- C. Brinkmann
- David L. Paterson
- Richard J. Fair
- Y. Tor
Citations in the corpus
- Development of nanoparticles for antimicrobial drug delivery. (2010, background): “Antibiotic efflux is a widely accepted mechanism of microbial drug resistance, in which proteinaceous transports located in bacterial membranes preferentially pump antimicrobial drugs out of the cells [27].”
- Predictive compound accumulation rules yield a broad-spectrum antibiotic (2017, background): “5: (1) ATCC 29213; (2) NRS3; (3) MG1655, (4) ELZ4017; (5) ELZ4045; (6) ELZ4346; (7) ELZ4081; (8) ELZ4072; (9) ELZ4239; (10) BAA-2469; (11) ATCC 19606; (12) KB304; (13) KB349; (14) WO22; (15) BD335; (16) IF101; (17) ATCC 27736; (18) 4-38; (19) 6-73; (20) ATCC 29893; (21) 1-60; (22) 3-46; (23) PAO1.”
- The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. (2012, background): “Multidrug-resistant (MDR) strains of pathogenic bacteria emerge with increasing frequency in hospitals and the general community alike [1].”
- Antimicrobial Resistance in ESKAPE Pathogens (2020, background): “The global financial antibiotic market, estimated at $30 billion, is still dominated by classes of antibiotics discovered over half a century ago (371).”
- Antibiotics induce redox-related physiological alterations as part of their lethality (2014, neutral): “Antimicrob Agents Chemother 53(4):1395–1402.”
- Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing (2015, background): “With the rise of drug-resistant bacterial infections and the sharp decline in antibiotic discovery and development (Fischbach and Walsh, 2009), phage therapy is regaining attention after years of declining interest (Carlton, 1999; Lu and Collins, 2007, 2009).”